Baxter International (NYSE:BAX) had its target price upped by Barclays from $72.00 to $75.00 in a research report sent to investors on Monday morning, BenzingaRatingsTable reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

Several other brokerages have also commented on BAX. Morgan Stanley boosted their price target on shares of Baxter International from $80.00 to $83.00 and gave the stock an overweight rating in a report on Tuesday, March 5th. Zacks Investment Research lowered shares of Baxter International from a buy rating to a hold rating in a report on Thursday, January 3rd. Credit Suisse Group initiated coverage on shares of Baxter International in a report on Monday, December 17th. They issued an outperform rating and a $77.00 price target for the company. Piper Jaffray Companies reissued an overweight rating and issued a $80.00 price target on shares of Baxter International in a report on Friday, February 1st. Finally, Citigroup raised shares of Baxter International from a neutral rating to a buy rating and boosted their price target for the stock from $69.00 to $76.00 in a report on Wednesday, January 2nd. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Baxter International currently has an average rating of Buy and an average price target of $78.31.

BAX opened at $79.61 on Monday. The company has a quick ratio of 1.50, a current ratio of 2.09 and a debt-to-equity ratio of 0.44. Baxter International has a 1 year low of $61.05 and a 1 year high of $82.25. The firm has a market capitalization of $40.84 billion, a P/E ratio of 26.10, a PEG ratio of 1.94 and a beta of 1.02.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Baxter International had a net margin of 14.60% and a return on equity of 19.10%. As a group, equities research analysts forecast that Baxter International will post 3.27 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date was Thursday, February 28th. Baxter International’s payout ratio is 24.92%.

In other news, Director Peter S. Hellman sold 5,680 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $81.89, for a total transaction of $465,135.20. Following the completion of the sale, the director now owns 28,774 shares of the company’s stock, valued at $2,356,302.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas T. Stallkamp sold 1,638 shares of the company’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $73.75, for a total transaction of $120,802.50. The disclosure for this sale can be found here. Insiders have sold 98,286 shares of company stock valued at $7,399,039 in the last ninety days. Insiders own 0.70% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in BAX. Gofen & Glossberg LLC IL grew its holdings in shares of Baxter International by 6.9% in the fourth quarter. Gofen & Glossberg LLC IL now owns 15,493 shares of the medical instruments supplier’s stock valued at $1,020,000 after purchasing an additional 1,004 shares during the period. First Financial Corp IN grew its holdings in shares of Baxter International by 11.9% in the fourth quarter. First Financial Corp IN now owns 1,875 shares of the medical instruments supplier’s stock valued at $124,000 after purchasing an additional 200 shares during the period. Round Table Services LLC grew its holdings in shares of Baxter International by 19.9% in the first quarter. Round Table Services LLC now owns 4,015 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 666 shares during the period. Westpac Banking Corp grew its holdings in shares of Baxter International by 0.7% in the fourth quarter. Westpac Banking Corp now owns 242,512 shares of the medical instruments supplier’s stock valued at $15,962,000 after purchasing an additional 1,659 shares during the period. Finally, Retirement Systems of Alabama grew its holdings in shares of Baxter International by 1.3% in the fourth quarter. Retirement Systems of Alabama now owns 316,143 shares of the medical instruments supplier’s stock valued at $20,809,000 after purchasing an additional 4,133 shares during the period. 86.41% of the stock is owned by institutional investors and hedge funds.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: What are different types of coverage ratios?

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.